Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Input: Consider Input: The tradition of birthday parties started in Europe a long time ago. It was feared that evil spirits were particularly attracted to people on their birthdays. To protect them from harm, friends and family members would come to stay with the birthday person and bring good thoughts and wishes. Giving gifts brought even more good cheer to keep away from the evil spirits. This is how birthday parties began. The following are some countries' birthday traditions: Canada---Putting butter on the nose. In Atlantic Canada, the birthday child's nose is put butter on for good luck. China---Noodles for lunch. The birthday child pays respect to his / her parents and receives a gift of money. Friends and relatives are invited to lunch and noodles are served to wish the birthday child a long life. England---Money cakes. Certain symbolic objects are mixed into the birthday cake as it is being prepared. If your piece of cake has a coin in it, you will be rich. Ireland---Birthday bump . The birthday child is lifted upside down and " bumped" on the floor for good luck. Italy---Pulling ears. The child's ears are pulled as many times as how old he / she is turning. Japan---New clothes. The birthday child wears new clothes to mark the occasion. New Zealand---Birthday claps. After the candles are hit, the happy birthday song is sung loudly and often out of tune and then the birthday person receives a clap for each year he / she has been alive and then one for good luck. The United States---Cake, candles and the birthday song. A cake is made, and candles are put on top based on how old the person is.

Output: According to the passage, in which country can the birthday children probably receive a gift of money?


Input: Consider Input: Empagliflozin is an orally available, potent and highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2). This study was undertaken to investigate the effect of food on the pharmacokinetics of 25 mg empagliflozin and to assess dose proportionality between 10 mg and 25 mg empagliflozin under fasted conditions. In this open-label, 3-way, cross-over study, 18 healthy volunteers received 3 single doses of empagliflozin in a randomized sequence (25 mg empagliflozin under fasted conditions, 25 mg empagliflozin after a high-fat, high-calorie breakfast and 10 mg empagliflozin under fasted conditions), each separated by a washout period of at least 7 days. Serial plasma samples were collected at selected time points over a period of 72 hours. Administration with food had no clinically relevant effect on the area under the plasma concentration-time curve (AUC0-) of empagliflozin (geometric mean ratio (GMR): 84.04, 90% confidence interval (CI): 80.86 - 87.34). The decrease observed in the maximum plasma concentrations (Cmax) of empagliflozin (GMR: 63.22, 90% CI: 56.74 - 70.44) when administered with food was not considered clinically meaningful. The increases in AUC0- and Cmax for 10 mg vs. 25 mg empagliflozin administered under fasting conditions were roughly dose-proportional, as demonstrated by the slope of the regression lines being slightly less than 1 (slope for AUC0-: 0.94, 95% CI: 0.90 - 0.97; slope for Cmax: 0.91, 95% CI: 0.80 - 1.01). Empagliflozin was well tolerated under fed and fasting conditions. The results support administration of empagliflozin tablets independently of food. Increases in empagliflozin exposure under fasting conditions were roughly dose-proportional between 10 mg and 25 mg empagliflozin.

Output: Which protein does empagliflozin inhibit?


Input: Consider Input: Osteoporosis and several other bone disorders occur when there is an imbalance between the resorption and formation components of bone remodeling activity. Therapies available for some of these conditions modulate the activity of osteoclasts and/or osteoblasts. The recent discoveries of receptor activator of NF-kappaB ligand (RANKL), an endogenous activator of osteoclastogenenesis and osteoclast activity and its inhibitor, osteoprotegerin (OPG) as pivotal regulatory factors in the pathogenesis of bone diseases like osteoporosis provide unique targets for therapeutic agents. In laboratory animals and now in humans, administering forms of OPG markedly inhibits osteoclast activity and improves bone strength, documenting that the strategy of inhibiting RANKL activity has therapeutic promise. A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density. Attributes of denosumab in these clinical studies include a very rapid onset of action, sustained effects for several months after a single injection, and good tolerability. These results provide the basis for studies evaluating the effectiveness of denosumab in several clinical conditions characterized by increased osteoclastic activity.


Output: To the ligand of which receptors does Denosumab (Prolia) bind?